201 related articles for article (PubMed ID: 32432234)
1. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
Cai M; Li B; Lin L; Huang J; An Y; Huang W; Zhou Z; Wang Y; Shuai X; Zhu K
Biomater Sci; 2020 Jun; 8(12):3485-3499. PubMed ID: 32432234
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
Li Y; Wei J; Wei Y; Cheng L; Guo B; Meng F; Li F; Zhong Z
Biomacromolecules; 2020 Feb; 21(2):716-724. PubMed ID: 31809037
[TBL] [Abstract][Full Text] [Related]
3. MRI-visible and pH-sensitive micelles loaded with doxorubicin for hepatoma treatment.
Li B; Cai M; Lin L; Sun W; Zhou Z; Wang S; Wang Y; Zhu K; Shuai X
Biomater Sci; 2019 Mar; 7(4):1529-1542. PubMed ID: 30681081
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
5. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
8. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
9. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
Su Y; Wang K; Li Y; Song W; Xin Y; Zhao W; Tian J; Ren L; Lu L
Nanomedicine (Lond); 2018 May; 13(9):1009-1023. PubMed ID: 29630448
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
Wang T; Zhang J; Hou T; Yin X; Zhang N
Nanoscale; 2019 Aug; 11(29):13934-13946. PubMed ID: 31305839
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
13. Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.
Wu H; Wang C; Sun J; Sun L; Wan J; Wang S; Gu D; Yu C; Yang C; He J; Zhang Z; Lv Y; Wang H; Yao M; Qin W; Wang C; Jin H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43996-44006. PubMed ID: 31682099
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
16. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical tumor acidity-responsive self-assembled magnetic nanotheranostics for bimodal bioimaging and photodynamic therapy.
Yang HY; Jang MS; Li Y; Fu Y; Wu TP; Lee JH; Lee DS
J Control Release; 2019 May; 301():157-165. PubMed ID: 30905667
[TBL] [Abstract][Full Text] [Related]
19. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
Zhang W; Cai J; Wu B; Shen Z
J Biomater Appl; 2019 Aug; 34(2):219-228. PubMed ID: 31084233
[No Abstract] [Full Text] [Related]
20. Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma.
Li Z; Ye L; Liu J; Lian D; Li X
Int J Nanomedicine; 2020; 15():1469-1480. PubMed ID: 32184599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
